​

Guardant Health (GH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GH Stock Forecast

Guardant Health (GH) stock forecast, based on 31 Wall Street analysts, predicts a 12-month average price target of $202.40, with a high of $225.00 and a low of $180.00. This represents a 24.22% increase from the last price of $162.94.

$50 $90 $130 $170 $210 $250 High: $225 Avg: $202.4 Low: $180 Last Closed Price: $162.94

GH Stock Rating

Guardant Health stock's rating consensus is Buy, based on 31 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 30 Buy (96.77%), 0 Hold (0.00%), 1 Sell (3.23%), and 0 Strong Sell (0.00%).

Buy
Total 31 1 30 Strong Sell Sell Hold Buy Strong Buy

GH Price Target Upside V Benchmarks

TypeNameUpside
StockGuardant Health24.22%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks1.69%

Price Target Trends

1M3M12M
# Anlaysts31659
Avg Price Target$206.67$201.63$157.49
Last Closing Price$162.94$162.94$162.94
Upside/Downside26.84%23.74%-3.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26520--126
Sep, 26519--125
Aug, 26519--125
Jul, 26519--125
Jun, 264161-122
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 12, 2026Kallum TitchmarshMorgan Stanley$200.00$162.9922.71%22.74%
Oct 07, 2026Luke SergottBarclays$220.00$170.6928.89%35.02%
Oct 01, 2026Guggenheim$200.00$177.2512.83%22.74%
Sep 10, 2026Eve BursteinBernstein$210.00$161.2530.23%28.88%
Sep 09, 2026UBS$225.00$160.9839.77%38.09%
Sep 08, 2026Redburn Partners$203.00$161.4125.77%24.59%
Aug 04, 2026Morgan Stanley$185.00$160.3615.37%13.54%
Aug 04, 2026Stephens$195.00$158.8322.77%19.68%
Aug 04, 2026Piper Sandler$193.00$158.8321.51%18.45%
Jul 31, 2026Dan LeonardRBC Capital$200.00$161.8723.56%22.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2026Roth CapitalBuyinitialise
Oct 12, 2026Morgan StanleyOverweightOverweighthold
Oct 07, 2026BarclaysOverweightOverweighthold
Oct 01, 2026GuggenheimBuyBuyhold
Sep 15, 2026Piper SandlerOverweightOverweighthold
Sep 10, 2026BernsteinOutperformOutperformhold
Aug 25, 2026Cowen & Co.BuyBuyhold
Aug 04, 2026Morgan StanleyOverweightOverweighthold
Aug 04, 2026StephensOverweightOverweighthold
Aug 04, 2026Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.80$-6.41$-4.28$-3.56$-3.32---
Avg Forecast$-4.26$-6.45$-3.58$-3.41$-2.90$-2.46$-2.32$-2.13
High Forecast$-4.11$-6.26$-3.49$-3.32$-2.26$-1.18$-0.24$-2.04
Low Forecast$-4.36$-6.80$-3.68$-3.50$-3.73$-2.99$-3.72$-2.29
Surprise %-10.80%-0.62%19.55%4.40%14.48%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$373.65M$449.54M$563.95M$739.02M$982.02M---
Avg Forecast$364.29M$446.54M$558.07M$729.04M$846.27M$1.02B$1.23B$1.46B
High Forecast$370.66M$464.85M$589.10M$729.24M$868.09M$1.02B$1.24B$1.54B
Low Forecast$354.33M$435.97M$538.39M$728.83M$819.82M$1.02B$1.22B$1.41B
Surprise %2.57%0.67%1.05%1.37%16.04%---

Net Income Forecast

$-700M $-560M $-420M $-280M $-140M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-405.67M$-654.59M$-479.45M$-436.37M$-416.28M---
Avg Forecast$-372.37M$-508.71M$-479.45M$-382.22M$-364.59M$-312.67M$-168.64M$-238.87M
High Forecast$-297.90M$-406.97M$-383.56M$-372.11M$-252.82M$-132.14M$-27.21M$-227.92M
Low Forecast$-446.85M$-610.45M$-575.34M$-392.33M$-417.56M$-334.31M$-416.51M$-256.14M
Surprise %8.94%28.68%-14.17%14.18%---

GH Forecast FAQ

Is Guardant Health stock a buy?

Guardant Health stock has a consensus rating of Buy, based on 31 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 30 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Guardant Health is a favorable investment for most analysts.

What is Guardant Health's price target?

Guardant Health's price target, set by 31 Wall Street analysts, averages $202.4 over the next 12 months. The price target range spans from $180 at the low end to $225 at the high end, suggesting a potential 24.22% change from the previous closing price of $162.94.

How does Guardant Health stock forecast compare to its benchmarks?

Guardant Health's stock forecast shows a 24.22% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (1.69%).

What is the breakdown of analyst ratings for Guardant Health over the past three months?

  • October 2026: 19.23% Strong Buy, 76.92% Buy, 0% Hold, 0% Sell, 3.85% Strong Sell.
  • September 2026: 20.00% Strong Buy, 76.00% Buy, 0% Hold, 0% Sell, 4.00% Strong Sell.
  • August 2026: 20.00% Strong Buy, 76.00% Buy, 0% Hold, 0% Sell, 4.00% Strong Sell.

What is Guardant Health’s EPS forecast?

Guardant Health's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.46, marking a -25.90% decrease from the reported $-3.32 in 2025. Estimates for the following years are $-2.32 in 2027, and $-2.13 in 2028.

What is Guardant Health’s revenue forecast?

Guardant Health's average annual revenue forecast for its fiscal year ending in December 2026 is $1.02B, reflecting a 4.01% increase from the reported $982.02M in 2025. The forecast for 2027 is $1.23B, and $1.46B for 2028.

What is Guardant Health’s net income forecast?

Guardant Health's net income forecast for the fiscal year ending in December 2026 stands at $-313M, representing a -24.89% decrease from the reported $-416M in 2025. Projections indicate $-169M in 2027, and $-239M in 2028.